EGFR and non-small cell lung carcinoma: Pan and co-workers demonstrated that primary (not acquired) resistance to the epidermal growth factor receptor (EGFR) TKI gefitinib22 in non-small cell lung cancer (NSCLC) cell lines was due, in part, to IGF1R signaling35.